180 Life Sciences Q2 2023 Earnings Report

180 Life Sciences EPS Results

• Actual EPS: -$13.30
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

180 Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

180 Life Sciences Announcement Details

• Quarter: Q2 2023
• Date: 8/15/2023
• Time: N/A

180 Life Sciences (NASDAQ:ATNF), a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.